A tripeptide derived from the C-terminal of alpha-MSH with anti-inflammatory and gut-protective effects, being studied for inflammatory bowel disease.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →KPV is a tripeptide composed of three amino acids: lysine (K), proline (P), and valine (V). It represents the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH), specifically the last three residues of that 13-amino acid peptide. This might seem like a minor structural footnote, but it turns out to be scientifically significant. Early researchers studying alpha-MSH discovered that its anti-inflammatory activity was concentrated in the C-terminal portion of the molecule, and KPV — as the minimal functional fragment retaining that activity — has since become a subject of focused research interest in its own right.
What makes KPV particularly interesting from a practical standpoint is what it lacks compared to its parent peptide. Alpha-MSH signals through melanocortin receptors (MC1R through MC5R) and drives melanin production as well as inflammation suppression. KPV, however, has markedly reduced affinity for melanocortin receptors at standard concentrations — meaning it retains the anti-inflammatory properties of alpha-MSH while largely avoiding the pigmentation effects that would be undesirable in chronic therapeutic use. This selectivity makes KPV a cleaner candidate for isolated anti-inflammatory applications.
Perhaps even more practically relevant is KPV’s unusual stability and bioavailability profile. As a tripeptide, KPV is compact enough to be transported across intestinal epithelial cells by the PepT1 oligopeptide transporter — the same transporter responsible for absorbing di- and tripeptides from dietary protein digestion. This means that unlike most peptides, which are degraded in the gastrointestinal tract, KPV can survive oral administration and reach intestinal epithelial cells and lamina propria immune cells in intact form. This is a rare and valuable characteristic in a peptide, and it is central to its research profile as a potential oral therapeutic for gut inflammation.
The conditions generating the most research interest around KPV are those involving mucosal inflammation: inflammatory bowel disease (IBD) including both Crohn’s disease and ulcerative colitis, intestinal permeability (“leaky gut”), and conditions where sustained disruption of the epithelial barrier contributes to systemic immune activation. KPV has also been studied topically for skin inflammation given that alpha-MSH plays a significant role in skin immune regulation through MC1R on keratinocytes and dermal immune cells.
KPV fits within a broader class of anti-inflammatory peptides under investigation for mucosal conditions. You can compare it to related compounds including VIP and BPC-157 in the Peptide Database. Those interested in applying KPV research to specific protocols can use the AI Peptide Coach for contextualized guidance.
The central molecular mechanism behind KPV’s anti-inflammatory effects is inhibition of nuclear factor kappa B (NF-κB) signaling — the same pathway targeted by many pharmaceutical anti-inflammatory drugs, but through a distinct mechanism. NF-κB is a transcription factor family that controls expression of hundreds of inflammatory genes including cytokines, chemokines, adhesion molecules, and enzymes like COX-2 and iNOS. Under resting conditions, NF-κB dimers are held in the cytoplasm by inhibitory proteins called IκBs. When a cell receives an inflammatory signal — from LPS, TNF-alpha, IL-1 beta, or other danger signals — a kinase complex called IKK (IκB kinase) phosphorylates IκB, flagging it for proteasomal degradation. Once IκB is removed, NF-κB is free to translocate to the nucleus and activate inflammatory gene transcription.
KPV interrupts this sequence by reducing IKK activity. Lower IKK activity means less IκB phosphorylation, more IκB retained in the cytoplasm, and less NF-κB entering the nucleus. The result is a dampened transcriptional response to inflammatory stimuli across the entire NF-κB target gene set. This is particularly significant in intestinal epithelial cells and macrophages in the lamina propria — the two cell populations most responsible for driving mucosal inflammation in IBD. Importantly, KPV does not appear to completely abolish NF-κB activity (which would impair innate immune defense against pathogens) but rather attenuates the amplitude of the response — consistent with the immunomodulatory rather than immunosuppressive category.
The PepT1 transporter (encoded by the SLC15A1 gene) is a proton-coupled oligopeptide transporter located on the apical surface of intestinal epithelial cells. Its evolutionary purpose is to absorb small peptides (dipeptides and tripeptides) from dietary protein digestion in the intestinal lumen, facilitating nutritional amino acid recovery with high efficiency. KPV, as a tripeptide, is a structural match for PepT1 substrates. Research by Dalmasso and colleagues demonstrated that KPV is actively transported into intestinal epithelial cells via PepT1, reaching intracellular compartments where it then exerts its anti-inflammatory effects directly on the NF-κB signaling machinery inside the cell.
This intracellular mechanism has several important implications. First, it means KPV does not need to signal through a cell surface receptor in the conventional sense — it enters the cell and acts on intracellular signaling nodes directly. Second, PepT1 expression is upregulated in inflammatory conditions including active IBD, which means KPV uptake may be enhanced precisely in the tissue states where it is most needed. Third, this transport route bypasses many of the peptide degradation pathways that destroy larger peptides before they can reach their target cells. The efficiency of PepT1 transport explains why KPV can be bioactive after oral administration at doses that would be trivially small for non-transported peptides.
Downstream of NF-κB suppression, KPV measurably reduces the intracellular production and secretion of three cytokines that are particularly important to intestinal inflammation: TNF-alpha, IL-1 beta, and IL-8. TNF-alpha is the proximal mediator of many IBD-associated inflammatory cascades and is the target of the most successful class of IBD biologics (infliximab, adalimumab, etc.). IL-1 beta drives NLRP3 inflammasome-dependent inflammation and epithelial damage. IL-8 is the primary neutrophil chemoattractant responsible for the neutrophilic infiltration seen in active colitis. By reducing all three simultaneously through NF-κB suppression rather than targeting any one specifically, KPV provides broad-spectrum attenuation of the mucosal inflammatory response.
Cell culture studies using human intestinal epithelial cell lines (Caco-2, HT-29, T84) stimulated with LPS, TNF-alpha, or IL-1 beta have consistently shown that pre-treatment or co-treatment with KPV significantly reduces cytokine output and preserves tight junction protein expression — a direct measure of epithelial barrier integrity. The protection of tight junction proteins (ZO-1, occludin, claudins) is particularly relevant to the leaky gut paradigm, where increased intestinal permeability allows luminal antigens to enter the lamina propria and perpetuate immune activation.
The most extensively studied application of KPV is in models of inflammatory bowel disease, particularly ulcerative colitis. Two widely used animal models — dextran sodium sulfate (DSS)-induced colitis and trinitrobenzene sulfonic acid (TNBS)-induced colitis — have been used to evaluate KPV across multiple research groups. In both models, KPV administration has consistently produced meaningful reductions in disease activity. Key endpoints that improve with KPV treatment include: colon weight-to-length ratio (a proxy for mucosal edema and inflammation), histological colitis scoring (evaluating crypt architecture, immune cell infiltration, and ulceration), mucosal cytokine concentrations, and stool consistency and blood scores.
A particularly elegant aspect of some of these studies is the oral administration route. Researchers at the University of Tennessee demonstrated that orally delivered KPV-loaded nanoparticles produced greater efficacy than free KPV, presumably by protecting the peptide from any residual gastrointestinal degradation and delivering it specifically to inflamed colonic tissue. The loaded nanoparticle approach exploits the enhanced permeability and retention characteristics of inflamed mucosa — the same principle used in some targeted drug delivery systems. Even without nanoparticle encapsulation, free KPV administered orally has shown significant anti-inflammatory effects in acute colitis models, consistent with its PepT1-mediated absorption.
Beyond reducing active inflammation, KPV has demonstrated an ability to accelerate mucosal healing — the restoration of intact epithelial architecture after injury. This is an important distinction from pure anti-inflammatory agents, which may suppress symptoms without actually repairing the damaged tissue. In wound healing assays using intestinal epithelial cell monolayers, KPV treatment accelerated cell migration into scratch wounds and increased epithelial cell proliferation rates. In animal colitis models, KPV-treated animals showed faster histological recovery with more complete crypt restoration compared to controls.
The mechanism behind this healing acceleration is not entirely characterized, but likely involves multiple pathways: reduced inflammatory cytokine burden (removing an obstacle to healing), direct effects on epithelial cell survival signaling, and possible upregulation of mucosal growth factors. Some research has pointed to KPV’s effects on TGF-beta signaling — a cytokine that is simultaneously important for mucosal healing and immune regulation — as a potential contributor to its tissue-regenerative properties. The combination of anti-inflammatory and pro-healing properties makes KPV potentially well-suited to IBD contexts where both active disease suppression and mucosal restoration are treatment goals.
Intestinal permeability — the “leaky gut” concept — describes a state where the tight junction complexes connecting intestinal epithelial cells are disrupted, allowing luminal contents including bacteria, bacterial products, and dietary antigens to pass through the epithelial barrier and into the lamina propria. This drives local and eventually systemic immune activation and is implicated not only in IBD but in a wide range of conditions including IBS, food sensitivities, autoimmune diseases, and systemic inflammatory states.
KPV has been studied specifically for its effects on tight junction protein expression and epithelial permeability. In cell culture models challenged with inflammatory stimuli or bacterial products, KPV treatment preserved expression of ZO-1, occludin, and claudin-1 — the primary structural proteins of tight junctions — compared to untreated controls. In animal models with disrupted barrier function, KPV reduced FITC-dextran permeability (a standard measure of paracellular flux) and decreased serum concentrations of LPS-binding protein (a marker of bacterial translocation). These findings suggest that KPV may address not just the inflammatory response to leaky gut but also the upstream structural integrity that prevents it.
Given that alpha-MSH plays a well-characterized role in skin immune regulation through MC1R on keratinocytes, melanocytes, and dermal immune cells, it is logical to explore whether KPV — its C-terminal fragment — retains any skin-relevant activity. Research in contact hypersensitivity models (a standard measure of skin inflammatory responses) has shown that topical KPV reduces ear swelling, edema, and histological inflammation scores. KPV also reduced epidermal cytokine expression including TNF-alpha and IL-6 in sensitized skin challenged with hapten antigens.
For wound healing, KPV has been incorporated into topical formulations and shown to reduce inflammatory cell infiltration in healing wounds while preserving re-epithelialization rates — a favorable combination suggesting it doesn’t impair the healing process while reducing excessive inflammation. Potential topical applications include inflammatory skin conditions such as atopic dermatitis, psoriasis, and contact dermatitis, as well as post-procedural skin recovery. The lack of melanogenic activity (compared to full alpha-MSH) makes KPV particularly attractive for skin applications where pigmentation changes would be undesirable.
While KPV’s most compelling data is gastrointestinal, its mechanisms are not inherently gut-specific. NF-κB suppression and cytokine reduction are relevant wherever macrophages, dendritic cells, and epithelial cells are driving pathological inflammation. Some research has examined KPV in the context of systemic inflammatory conditions, showing that it reduces circulating inflammatory cytokines in models of systemic LPS challenge. There is also theoretical interest in KPV for neuroinflammation — given that the same NF-κB pathway drives microglial activation in brain inflammation — though CNS-directed research on KPV specifically is limited. The peptide’s small size and potential PepT1-like transport mechanisms in other tissues may broaden its distribution beyond the gut, but characterization of these systemic effects remains less complete than the gastrointestinal research.
The oral route is uniquely viable for KPV compared to most peptides, and the available preclinical research suggests that this route is not only practical but may offer targeted delivery to intestinal tissue via the PepT1 transport mechanism. Research studies in animal models have used oral KPV doses ranging from approximately 0.1 to 1 mg/kg, with clear efficacy signals in IBD models at these ranges. Human equivalent dose extrapolations based on body surface area conversion from rodent models suggest that oral doses in the range of a few hundred micrograms to low milligrams per day may be relevant for gut-directed applications, though formal human dose-finding studies are not yet available. Oral KPV capsule preparations have been used in research contexts and have the practical advantage of stability in solid dosage form, easier handling, and no reconstitution requirement.
For research contexts where systemic exposure is desired rather than primarily gut-targeted effects, subcutaneous injection of KPV has been used. Because KPV is a small tripeptide, it may be somewhat more susceptible to rapid degradation than larger peptides even via the subcutaneous route, though its small size also means tissue penetration is generally efficient. Research protocols using subcutaneous KPV have typically used doses in the range of 100–500 micrograms once or twice daily. The peptide should be reconstituted in bacteriostatic water for injections and prepared aseptically. Dosage calculations for research use can be worked through using the Peptide Dosage Calculators.
Topical KPV preparations have been studied primarily for skin inflammation. The tripeptide’s small molecular weight facilitates epidermal penetration compared to larger peptides, and it can be incorporated into standard topical bases including gels, creams, and liposomal serums. Research formulations have used KPV concentrations ranging from 0.01% to 0.1% w/w in topical carriers. For wound healing applications, KPV has been incorporated into hydrogel dressings to provide sustained local release to the wound bed. Topical application avoids systemic exposure entirely, making it the lowest-risk administration route from a safety standpoint.
An emerging area of KPV delivery research involves loading the tripeptide into nanoparticle carriers — particularly colitis-targeted nanoparticles designed to preferentially accumulate in inflamed intestinal tissue. Hydrogel nanoparticles functionalized with ligands that bind to markers overexpressed on inflamed colonocytes or macrophages have been shown to dramatically improve KPV efficacy in colitis models compared to free peptide. While nanoparticle-formulated KPV is not yet available as a mainstream research reagent, this approach represents the pharmaceutical development direction for KPV as a potential IBD therapeutic. The enhanced permeability and retention of inflamed mucosa means that even unfunctionalized nanoparticles passively accumulate at sites of colitis, improving targeted delivery without complex receptor targeting.
KPV’s safety profile in preclinical research is notable for the absence of significant adverse findings at doses used in efficacy studies. As a tripeptide naturally occurring as the C-terminal portion of alpha-MSH — an endogenous peptide — KPV does not represent a foreign structural motif. Animal studies have not identified organ toxicity, hematological abnormalities, or significant behavioral changes at anti-inflammatory doses. The reduced affinity for melanocortin receptors compared to full alpha-MSH means that the hormonal and pigmentation effects of MC1R and MC4R activation (appetite regulation via MC4R, melanin synthesis via MC1R) are largely absent at relevant KPV concentrations. This is an important safety advantage over full-length alpha-MSH.
One consideration specific to orally administered KPV is the possibility of GI tolerance variability across individuals. While the PepT1 transport mechanism is broadly conserved, individual variation in PepT1 expression and gastrointestinal transit time could affect absorption and local tissue concentrations. Given that KPV is intended to act on the intestinal mucosa, these variables could influence efficacy more than safety.
Because KPV suppresses NF-κB signaling and reduces TNF-alpha and other cytokines, there is a theoretical concern that prolonged or high-dose use could impair immune defense against infections. This concern is well-established with pharmaceutical NF-κB pathway inhibitors and biological anti-TNF agents used in IBD, which carry known infection risk. Whether KPV’s more modest and indirect NF-κB modulation produces meaningful immunosuppression is unknown — preclinical studies have not reported increased infection susceptibility, but long-term human data is not available. Users in research contexts should be aware of this potential consideration, particularly if combining KPV with other immunomodulatory compounds. Periodic monitoring of immune function markers would be prudent in extended research applications.
No formal drug interaction studies for KPV have been published. Theoretically, combining KPV with other NF-κB inhibitors or immunosuppressive agents could produce additive immunosuppression. Of particular relevance for IBD research contexts, combining KPV with corticosteroids or biologics (anti-TNF agents, JAK inhibitors) could produce unpredictable additive effects on immune suppression. Contraindications are not formally established given limited human data, but caution would be warranted in active serious infections, known immunodeficiency states, and pregnancy (given the general lack of pregnancy safety data for research peptides). The AI Peptide Coach can provide more context on combining KPV with other compounds in research frameworks.
Alpha-MSH is a 13-amino acid peptide with broad melanocortin receptor activity. Its binding to MC1R drives melanin production in skin and hair cells, and its MC4R activity influences appetite and energy balance. If you want specifically anti-inflammatory effects without the pigmentation side effects or neuroendocrine signaling of full alpha-MSH, KPV is the better tool. Researchers and clinicians who have explored alpha-MSH have sometimes encountered unwanted tanning as a side effect. KPV retains the anti-inflammatory C-terminal sequence while having greatly reduced melanocortin receptor affinity, making it a more targeted option for isolated anti-inflammatory research purposes.
This is a critical question, and the evidence suggests yes — at least partially. The PepT1 transport mechanism explains why: by virtue of being a tripeptide matching the substrate profile of a constitutively active intestinal transporter, KPV gets actively imported into epithelial cells before it has time to be fully hydrolyzed. Larger peptides don’t have this advantage and are degraded before absorption. KPV’s stability is also enhanced by the proline residue in the middle of the sequence — proline is uniquely resistant to proteolytic cleavage by most serine and cysteine proteases due to its cyclic side chain, which introduces a structural constraint that blocks enzymatic attack. This combination of transporter-mediated uptake and proline-enhanced stability gives KPV a meaningful oral bioavailability that is not shared by most research peptides.
Both KPV and BPC-157 are studied for gut health and mucosal healing, but they work through completely different mechanisms and likely have non-overlapping effects. BPC-157 promotes angiogenesis, modulates nitric oxide systems, and accelerates tissue repair with a strong tendon and connective tissue component alongside GI effects. KPV works specifically through NF-κB/IκB suppression and PepT1-mediated intracellular cytokine reduction — it is fundamentally an anti-inflammatory agent with mucosal healing secondary effects. BPC-157 has more evidence for structural tissue repair; KPV has more targeted evidence for mucosal immune modulation. They are conceptually complementary rather than redundant, though no human studies have formally evaluated the combination.
The most robust research for KPV is gut-specific, largely because PepT1 expression drives its oral bioavailability and targets it to intestinal tissue. However, NF-κB suppression is relevant in virtually every inflammatory tissue, and subcutaneous administration would deliver KPV systemically. Topical KPV has been studied for skin inflammation with promising results. For systemic inflammatory conditions, the tripeptide’s small size and general anti-inflammatory mechanism suggest broader potential, though the gut and skin are currently the most evidence-supported applications. Research into KPV for neuroinflammation, joint inflammation, and other systemic applications is in early stages.
KPV is a relatively simple tripeptide (K-P-V) that can be synthesized using standard solid-phase peptide synthesis and is commercially available from peptide research suppliers in both powder and capsule form. Purity verification via HPLC and mass spectrometry should be confirmed before use. Oral capsule forms are available from some suppliers and have been used in clinical-adjacent research settings. Lyophilized powder forms require reconstitution and are used for injectable preparations. Given that KPV is a tripeptide rather than a complex polypeptide, synthesis costs are relatively low and quality control is more straightforward than for larger peptides.
Lyophilized (freeze-dried) KPV powder has excellent stability at room temperature for short periods and should be stored at 2–8°C for longer-term storage. Once reconstituted, solutions should be kept at 2–8°C and used within 28 days to ensure potency. Oral capsule forms in solid dosage form are generally more stable than reconstituted solutions and can typically be stored at room temperature away from heat and humidity. As with all peptides, avoiding freeze-thaw cycling once reconstituted is advisable. Proper storage protocols help ensure that the peptide remains structurally intact and biologically active at the time of use.
Alpha-MSH is derived from POMC (pro-opiomelanocortin), the precursor protein that also generates ACTH, beta-endorphin, and other melanocortins. The 13-amino acid alpha-MSH sequence contains multiple functional domains — the N-terminal acetyl modification contributes to receptor binding, the central His-Phe-Arg-Trp core (positions 6–9) is critical for melanocortin receptor activation, and the C-terminal Lys-Pro-Val (KPV) segment contributes to anti-inflammatory activity. By studying KPV independently, researchers have been able to isolate and characterize the anti-inflammatory signaling of this fragment without the receptor-binding complications of the full molecule. KPV thus represents a reductionist approach to leveraging alpha-MSH biology that is increasingly common in peptide research.
The Peptide Database includes KPV alongside VIP, BPC-157, and other mucosal and anti-inflammatory peptides. For research planning, the AI Peptide Coach can help contextualize KPV’s role within a broader protocol. Dosage and reconstitution questions can be addressed using the Peptide Dosage Calculators.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.